# ViewsML

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viewsml

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.viewsml.com/
- Total disclosed funding: $4.9M
- Latest round: Seed (Apr 20, 2026)
- Investors on record: 8

## About

Based in Canada, ViewsML delivers AI-driven virtual biomarker staining solutions designed to enhance cancer diagnostics and research, offering rapid and precise results that support precision medicine initiatives.Founded in 2022 and headquartered in Vancouver, Canada, ViewsML specializes in artificial intelligence-based diagnostic solutions. The company has successfully closed 2 deals and raised a total of USD 4.90 mn in funding, with its latest Seed round led by Wittington Ventures, alongside investors including Continuum Health Ventures and Mayo Clinic Ventures.ViewsML focuses on advanced diagnostic solutions that leverage artificial intelligence to improve cancer treatment and research. Its flagship product, virtual biomarker staining, utilizes deep learning algorithms to provide rapid and accurate results, eliminating the need for traditional physical staining methods. This innovation accelerates biomarker identification, crucial for precision medicine, allowing clinicians and researchers to delve deeper into cellular mechanisms. The company serves a broad clientele, including pharmaceutical firms, clinical labs, and research institutions, predominantly in oncology. Its products are marketed across North America, Europe, and select Asia-Pacific markets to address global cancer diagnostic challenges.ViewsML generates revenue through a B2B model, partnering with healthcare providers and research institutions. Clients access its virtual biomarker staining platform via subscription, enabling diagnostic tests with results delivered faster and at lower costs than traditional methods. Collaborations with clinical labs integrate this technology into existing workflows, enhancing diagnostic capabilities. The pricing structure reflects the innovative nature of its services, ensuring cost-effective solutions for precision medicine while remaining competitive within the industry.ViewsML aims to introduce new products designed to expand its offerings in the cancer diagnostics field. The company plans to enter new markets, particularly targeting regions in Europe and Asia-Pacific by the end of 2024. The recent funding round will support these expansion efforts and facilitate the development of additional diagnostic innovations, enhancing their technological capabilities and market reach.

## Funding rounds

- Seed, Apr 20, 2026, $4.9M — Mayo Clinic Ventures, Debiopharm Innovation Fund, Wittington Ventures, WUTIF Capital (VCC), E-Fund, RiSC Capital Corp, Continuum Health Ventures, Defined Capital

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Seed
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Seed
- Wittington Ventures (https://capitalatlas.ai/funds/wittington-ventures) — Seed
- WUTIF Capital (VCC) (https://capitalatlas.ai/funds/wutif-capital-vcc) — Seed
- E-Fund — Seed
- RiSC Capital Corp (https://capitalatlas.ai/funds/risc-capital-corp) — Seed
- Continuum Health Ventures (https://capitalatlas.ai/funds/continuum-health-ventures) — Seed
- Defined Capital (https://capitalatlas.ai/funds/defined-capital) — Seed